Weight loss medications that target the hormone GLP-1 have transformed obesity treatment in recent years. Drugs such as Wegovy and Ozempic are widely prescribed to help patients reduce body weight, improve blood sugar control, and lower cardiovascular risks.
However, one common concern among patients is whether these medications must be taken every week for life. A small new study suggests that some patients who have already lost weight on GLP-1 drugs may be able to maintain their results while taking injections less frequently.
While the findings are still early and require further research, they raise interesting questions about personalized dosing schedules for weight management treatments.
GLP-1 medications mimic a hormone known as glucagon-like peptide-1. This hormone plays an important role in appetite regulation, insulin release, and blood sugar control.
Drugs such as Wegovy and Ozempic work by:
Because of these effects, many patients experience significant weight loss along with improved metabolic health markers.
These medications are typically administered as once-weekly injections, and treatment is often recommended as a long-term strategy to maintain results.
Yet the idea of lifelong weekly injections raises concerns for some people. Cost, insurance coverage, and convenience are common factors influencing whether patients continue treatment.
The research was led by Mitch Biermann, an obesity and internal medicine specialist at Scripps Clinic in San Diego.
The idea for the study began when several patients mentioned that they had started spacing out their GLP-1 injections rather than taking them weekly.
Interestingly, these individuals reported that they were still maintaining their weight loss even after extending the interval between doses.
After hearing similar reports from multiple patients, Biermann decided to review their medical records to see whether the trend appeared consistent.
The results were published in the scientific journal Obesity.
The study examined 34 patients who had already lost weight using GLP-1 medications.
Instead of stopping treatment completely, these patients gradually began taking their injections less frequently.
Researchers then tracked their health data for 36 weeks to observe what happened to their weight and metabolic health.
These outcomes suggest that reduced dosing schedules might work for certain individuals once they reach their weight loss goals.
Body Mass Index (BMI) is commonly used to categorize weight status.
At the beginning of their treatment, the participants had an average BMI of 30, which falls within the obesity range.
After losing weight on GLP-1 therapy, their BMI dropped to 25.2, placing them in the overweight category.
By the end of the study period, the average BMI had decreased further to 24.6, which falls within the normal weight range.
These results indicate that many patients were able to maintain or even improve their weight status despite taking injections less frequently.
Patients in the study followed several different dosing schedules after reducing their injection frequency.
These included:
The longest interval reported in the study was six weeks between injections.
While most patients maintained their weight, only a small number experienced weight regain.
In those cases, individuals simply returned to the standard weekly dosing schedule.
One study participant, Scott McMillin, had struggled with weight management for many years.
After starting weekly injections of Wegovy in 2023, he lost about 20 pounds. His blood pressure and cholesterol levels also improved significantly.
When McMillin tried stopping the medication entirely, however, he regained about 10 pounds.
Later, he restarted treatment and eventually experimented with spacing injections to every two weeks.
According to McMillin, the change made little difference in maintaining his weight.
He also adopted several lifestyle habits to support his progress, including:
This combination of medication and lifestyle changes may have contributed to his ability to maintain results.
Experts say several factors could explain why certain individuals maintain weight loss with fewer injections.
One possible explanation is that patients who reach their target weight often develop sustainable lifestyle habits during treatment.
These may include healthier eating patterns, regular exercise, and improved metabolic function.
Another possibility is that some individuals respond more strongly to GLP-1 medications than others.
Fatima Stanford, an obesity specialist at Harvard Medical School, noted that patients who successfully reduce their dosing frequency may already be highly motivated and consistent with healthy behaviors.
She also suggested that these individuals may be metabolically more responsive to the medication.
While the findings are encouraging, researchers caution that reduced dosing will not work for everyone.
In the study, about 12 percent of patients eventually returned to weekly injections after gaining some weight back.
This highlights an important point: GLP-1 medications remain a long-term treatment for many people.
Stopping medication completely often leads to weight regain, which has been observed in several previous studies.
Instead, the research suggests that personalized dosing schedules may be possible for certain patients once they achieve their desired results.
Despite the promising findings, the study had several important limitations.
First, the sample size was small, with only 34 participants.
Second, the research relied on existing medical records rather than a randomized clinical trial. This means researchers did not compare the results with a control group.
Additionally, most participants were white and privately insured, which may limit how broadly the results apply to other populations.
Because of these factors, larger and more rigorous studies will be needed to confirm whether reduced dosing strategies work widely.
GLP-1 medications have become extremely popular in recent years because of their effectiveness.
However, several factors make long-term weekly treatment challenging for some people.
These medications can be expensive, particularly when insurance coverage is limited.
Coverage policies vary widely, and some patients lose coverage after achieving weight loss goals.
Many people are uncertain about committing to weekly injections indefinitely.
According to researchers, these concerns are common among patients considering treatment.
Despite the growing popularity of medications like Ozempic and Wegovy, usage remains relatively low.
Studies estimate that only about 6 percent of Americans currently use GLP-1 medications.
However, roughly 51 percent of adults in the United States meet the medical eligibility criteria for these treatments.
This gap highlights both the demand for effective obesity treatments and the barriers many patients face in accessing them.
The concept of individualized treatment plans is gaining attention in obesity medicine.
Rather than applying a single dosing schedule to all patients, doctors may eventually adjust treatment based on factors such as:
Some experts believe this approach could improve patient adherence while also reducing treatment costs.
However, larger clinical trials will be needed before reduced dosing strategies become part of official treatment guidelines.
Patients should never change their medication dosing schedule without consulting their healthcare provider.
GLP-1 medications affect multiple biological systems, and adjusting treatment without medical guidance could lead to unwanted side effects or weight regain.
Doctors may consider spacing out injections only after a patient:
Even then, ongoing monitoring is typically required.
GLP-1 medications like Wegovy and Ozempic have revolutionized the treatment of obesity and metabolic disease.
A small new study suggests that some patients may be able to maintain their weight loss while taking injections less frequently once they reach their target weight.
However, the research is still early, and reduced dosing strategies may not work for everyone.
For now, the findings open the door to a new conversation about personalized treatment plans for long-term weight management.
As larger studies emerge, doctors may gain clearer guidance on how to tailor GLP-1 therapy to individual patient needs.
This article is for informational and educational purposes only and should not be considered medical advice. Medical research findings describe general trends and may not apply to every individual. Always consult a qualified healthcare professional before making decisions about medications, treatments, or health management strategies.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.